New drug combo shows promise for tough breast cancer
Disease control
Completed
This study tested a combination of two drugs, ladiratuzumab vedotin and pembrolizumab, in 185 people with advanced triple-negative breast cancer that had spread. The main goals were to check for side effects and see how well the drugs shrank tumors. The trial was completed and pr…
Phase: PHASE1, PHASE2 • Sponsor: Seagen Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC